ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $102.14 Average Target Price from Analysts

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have received a consensus rating of “Moderate Buy” from the nine ratings firms that are currently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $102.1429.

A number of research firms have issued reports on ANIP. Barclays began coverage on ANI Pharmaceuticals in a research note on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price target for the company. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Weiss Ratings reiterated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, December 29th. JPMorgan Chase & Co. raised their price objective on ANI Pharmaceuticals from $95.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, September 24th. Finally, Truist Financial lifted their price objective on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the stock a “hold” rating in a report on Thursday, October 9th.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Chad Gassert sold 14,642 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $89.07, for a total value of $1,304,162.94. Following the completion of the sale, the senior vice president directly owned 158,584 shares of the company’s stock, valued at approximately $14,125,076.88. This represents a 8.45% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Meredith Cook sold 400 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $82.32, for a total value of $32,928.00. Following the completion of the transaction, the vice president directly owned 74,874 shares of the company’s stock, valued at approximately $6,163,627.68. This represents a 0.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 28,001 shares of company stock valued at $2,446,934 in the last quarter. 11.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of hedge funds have recently made changes to their positions in ANIP. Oliver Luxxe Assets LLC bought a new position in ANI Pharmaceuticals during the fourth quarter valued at about $1,823,000. Tudor Investment Corp ET AL purchased a new position in ANI Pharmaceuticals in the third quarter valued at about $1,085,000. Penn Capital Management Company LLC grew its position in shares of ANI Pharmaceuticals by 6.5% during the 3rd quarter. Penn Capital Management Company LLC now owns 6,364 shares of the specialty pharmaceutical company’s stock valued at $583,000 after acquiring an additional 387 shares during the period. Danske Bank A S bought a new position in shares of ANI Pharmaceuticals during the 3rd quarter valued at approximately $864,000. Finally, Advisory Services Network LLC purchased a new stake in shares of ANI Pharmaceuticals during the 3rd quarter worth approximately $366,000. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Trading Up 2.0%

NASDAQ ANIP opened at $81.04 on Tuesday. The company has a quick ratio of 2.04, a current ratio of 2.58 and a debt-to-equity ratio of 1.20. ANI Pharmaceuticals has a 52 week low of $52.74 and a 52 week high of $99.50. The business has a 50 day moving average price of $83.09 and a 200-day moving average price of $82.99. The company has a market cap of $1.82 billion, a price-to-earnings ratio of 49.72 and a beta of 0.51.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.74 by $0.30. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. The business had revenue of $227.81 million during the quarter, compared to the consensus estimate of $211.92 million. During the same quarter last year, the firm posted $1.34 EPS. ANI Pharmaceuticals’s revenue was up 53.6% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. As a group, equities analysts expect that ANI Pharmaceuticals will post 3.86 earnings per share for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.